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Putative Involvement of Thiol 




The intermolecular structure gets altered when drug-protein interaction takes 
place. It brings about alterations in the conformation of protein. An acetyl cho-
linesterase inhibitor (AChE) is the most used drug for patients who are suffering 
from Alzheimer’s disease to curb its instigated symptoms. So, it is used as first-line 
defense in the insightful symptoms. This study is of concern with the interaction 
of cystatin purified from buffalo brain with its simple tri-step procedure including 
alkaline action, ammonium sulfate fractionation, and gel filtration chromatography 
on Sephadex G-75 with % yield of 64.13 and fold purification of 384.7. The inhibi-
tor (brain cystatin (BC)) showed a single papain inhibitory peak drifted as single 
band on native PAGE; this purified inhibitor was interacted with donepezil to 
analyze the side effect of this drug since cystatin is an important regulatory protein 
that maintains the protease antiprotease balance. The conformational change was 
predicted when the UV spectra of cystatin was analyzed in the presence of donepe-
zil contextual with the fluorescence spectra, but the fluorescence spectra showed 
40 nm of red shift suggesting the change on interaction leading to a conclusion that 
donepezil is pertinent to imbalance to protease and antiprotease inhibitor perhaps 
the side effect of drug.
Keywords: acetyl cholinesterase (ach), acetyl cholinesterase inhibitor (AChE), 
Alzheimer’s disease (AD), brain cystatin, (BC), thiol protease inhibitor
1. Introduction
Brain is exposed to a variety of neuromodulating agents given as therapy. The 
consequential action of these agents should be investigated to have the knowledge 
of their side influence. The primary degenerative disease of brain is dementia 
subsequently causing Alzheimer’s disease. It is instigated in late life with cumulative 
properties like diminishing of memory, cognition, linguistic ability, and judgment. 
It is an advanced brain disorder relating to a person’s inability to learn, reason, and 
carry out daily activities [1, 2]. The significant neurotransmitter acetylcholine is 
associated with normal functioning of the brain, and if the level of acetylcholine 
goes down in the cerebral cortex, this promulgates to  Alzheimer’s disease, the 
debilitating brain condition [3, 4].
Alzheimer’s disease (AD) patients have lesser level of acetylcholine with 
the progressive abnormalities in cholinergic neurons. One line of attack to 
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reduce the impact of these abnormalities is to obstruct the relevant enzyme 
AChE (acetylcholinesterase) which acts as a foremost agent in the breakdown 
of acetylcholine (ACh) [2]. Acetylcholine hydrolysis into choline and acetate is 
prevented by AChE inhibitors in the synaptic clefts and ensuing in activating 
cholinergic transmission [3]. Donepezil (Figure 1) is a piperidine-class (piperi-
dine is a widely used building block and chemical reagent in the synthesis of organic 
compounds, including pharmaceuticals; piperidine is a widely used secondary amine) 
AChE inhibitor, sensibly designed especially for Alzheimer’s disease [5, 6].  
It is used to improve cognitive function in patients of AD and shows no sign of 
hepatotoxicity [7–9]. The trade name of this drug is Aricept and it functions as 
an acetylcholinesterase inhibitor [10]. It has 100% of an oral bioavailability and 
easily passes the blood–brain barrier. Shows the half life of 70 hrs. The primary 
action of donepezil is by plummeting the breakdown of acetylcholine thus 
amassing the concentration of acetylcholine in the brain retaining back to its 
normal function [11].
The major neuropathological hallmarks of AD are senile plaque, neurofibril-
lary tangles, and neuronal loss. Both cathepsins and cystatins (cystatin A and B) 
are found in close association with senile plague, cerebrovascular amyloid 
deposits, and neurofibrillary tangles in Alzheimer’s disease, Parkinson’s, and 
patients suffering from senile dementia supporting the fact that they are amyloid 
constituents. Recent researches have shown that cathepsins are one of the most 
important proteases involved in the processing of neuropeptides in the central 
nervous system (CNS) of brain (Figure 2) [12], while cystatin C is also existing 
in high concentration and their concentration relevant in brain diseases. Cysteine 
proteinases in normal persons help in 𝛽-peptide clearing. The disturbance between 
the accumulative action of cathepsins and cystatins may lead to aggregation of 
potentially amyloidogenic fragment collection aggravates to form amyloid fibrils 
in nerve cells of AD patients causing cystatin concentration to shrink (Figure 3). 
Generated by imbalance of cathepsins and cystatin, these potentially amyloido-
genic fragments at liberty into the extracellular space cause the aggravation of 
disease [12].
The powerful regulatory system is constituted by cystatins for endogenous 
cysteine proteinases (cathepsins) which are often permeable from the lysosomes of 
dying or diseased cells [13]. Cystatins are the natural inhibitors of cysteine pro-
teases with wide occurrence in tissues and cells which belong to a super family of 
proteins [14]. Cystatin super family has been divided into three families on the basis 
of homology, inhibition of target enzymes, and presence or absence of disulfide 
bonds.
Family 1, also called as stefins, includes members of low-molecular-weight pro-
teins (11 kDa) which lack disulfide bonds and carbohydrate contents. This family 
includes cystatins A and B and stefins C and D.
Figure 1. 
Structure of donepezil [17].
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The figure shows the detailed interaction of cystatin-cathepsin imbalance and 
the role of acetylcholine esterase inhibitor as function in restoration of Alzheimer’s 
diseases. They are found both in the body fluids and cells. Common illustration is 
cystatin C.
Kininogens or family 3 cystatins are large precursor molecules of the vasoactive 
kinins. They are glycoproteins of single chain that perform the multiple biologi-
cal functions such as kinin delivery, induction of endogenous blood coagulation 
cascade, and acute phase response intercession. They are inhabitants of blood 
plasma [15].
Figure 2. 
Graphical abstract – Showing the function of cystatin in brain, how it is combating the several diseases.
Figure 3. 
Graphical abstract-2.
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Cystatins tightly bind and impede the activity of cathepsins; if the activity of 
cathepsins is not regulated, it instigates chronic diseases [13]. Senile plaque, cere-
brovascular amyloid deposits, and neurofibrillary tangles in Alzheimer’s disease 
are all the ramifications of imbalance between proteinases and their endogenous 
inhibitor cystatins [1].
Normal functioning of the brain is balanced by maintaining the level of ace-
tylcholine and acetylcholinesterase inhibitor [16]. A previous report showed that 
donepezil binds along with HSA modifying it conformationally by effecting its free 
concentration in plasma [17].
The supplementation of donepezil was explored to find out any effect on 
cystatin (major regulator of thiol proteases: cathepsins B, H, and L, etc.) in the 
mammalian system. If the activity of these proteases is not controlled, it will lead 
to protease and antiprotease imbalance and repercussion to several diseases [18]. 
Therefore, it was thought worthwhile to investigate the donepezil cystatin binding 
and its role in the proper accomplishment of drug delivery and if it lead to kind 
of side effects as well as to gain knowledge about any conformational change in 
cystatin effecting its activity?
The study shows that the imbalance of protease-antiprotease purportedly 
leads the way to Alzheimer’s disease, while the presence of drug donepezil unfolds 
cystatin which becomes unfit to bind cathepsins leading to a number of diseases as 
a considerable side effect of the drug. As cystatins play significant role in several 
diseases like, cancer and cardiovascular diseases [19]. Therefore, the usage of 
donepezil in such patients requires additional attention.
2. Materials
Papain (99% purity) was obtained from Sigma Chemical Company (St. Louis, 
USA). Donepezil (an Alzheimer drug) was purchased from Ranbaxy (India). The 
solutions were prepared in 50 mM phosphate buffer of pH 7.4. Salts were purchased 
from Merck (India). The protein concentration was determined spectrophotometri-
cally. All other reagents were of analytical grade, and double distilled water was 
used throughout.
3. Methods
Purification of brain cystatins. Buffalo brain whole mass (150 g) was brought 
fresh from slaughter house in a box containing ice packs. It was carefully washed 
and rinsed with water, eliminating thin membrane and nerves by forceps, and the 
whole brain tissue was homogenized in 50 mM sodium phosphate buffer (300 mL) 
of pH 7.5 containing 0.15 M NaCl, 3 mM EDTA, and 2% n-butanol. After centrifu-
gation at 11,000 rpm for 15 min at 40°C, residue was cast off, and the supernatant 
was further processed. The procedure involved a combination of alkaline treatment 
(pH 11.0), ammonium sulfate fractionation, and gel filtration chromatography. The 
brain was homogenized and fractionated with ammonium sulfate between 40 and 
60% saturation; the precipitated protein was then dialyzed against 50 mM sodium 
phosphate buffer pH 7.4 containing 0.1 M NaCl. Elution profile showed two protein 
peaks—one major and one minor called as peak-I and peak-II. Peak-I is conforming 
to high-molecular-weight buffalo brain cystatin with significant inhibitory activity 
and protein content; however, peak-II with insignificant protein concentration and 
low inhibitory activity was not taken into consideration for further studies. Peak-I 
named as BC was purified with fold purification of 384.72 and yield of 64.13%. 
5Putative Involvement of Thiol Protease Inhibitor in the Function of Alzheimer Drug
DOI: http://dx.doi.org/10.5772/intechopen.83578
Papain inhibitory fractions of peak-I were pooled, concentrated, and checked for 
purity. Five milliliter fractions were collected and assayed for protein and cystatin 
activity. Homogeneity of the preparation was investigated by 7.5% PAGE [20].
4. Spectroscopic studies
4.1 Fluorescence spectra of brain cystatin with drug
Brain cystatin (BC) (1 𝜇M) was incubated for 30 min with subsequent higher 
concentration of donepezil in 0.05 M sodium phosphate buffer pH 7.5 in a final 
reaction volume of 1 mL at room temperature. The same buffer is used for prepara-
tion of drug solutions. Fluorescence measurements were carried out on a Shimadzu 
Spectroflourimeter model RF-5301PC (Shimadzu, Japan) equipped with a 150 W 
Xenon lamp and a slit width of 10 nm at 298 K. The fluorescence was recorded in 
wavelength region 300–400 nm after exciting the protein at 280 nm. The slits were 
set at 10 nm for excitation and emission. The path length of the sample was 1 cm.
4.2 UV spectra of cystatin in the presence of donepezil
The UV measurement of brain cystatin in the presence and absence of drug 
was made in the range of 200–300 nm, and the inhibitor (cystatin) concentration 
was fixed at 1 𝜇M, while the drug concentration was varied from 0.16 to 1.6 𝜇M. 
Absorption spectra were recorded on a double-beam Shimadzu UV-vis spectropho-
tometer UV-1700 using a cuvette of 1 cm path length.
4.3 Activity measurement of brain cystatin in the presence of donepezil
The inhibitory activity of the purified inhibitor (BC) under native conditions 
was assessed by its ability to inhibit caseinolytic activity of papain by the method 
of Kunitz [21]. The inhibitor (1 𝜇M) was incubated with increasing concentra-
tions of donepezil at 25°C for 30 min before the activity was measured. Activity of 
untreated BC was taken as 100%.
5. Results
5.1 Interaction of donepezil with brain cystatin
Alzheimer’s disease is a progressive brain disorder that gradually destroys a 
person’s memory and ability to learn, reason, and make judgments. AChE is respon-
sible for degradation of the neurotransmitter acetylcholine (ACh) in the synaptic 
cleft of neuromuscular junctions and of neuronal contacts in the central nervous 
system [22, 23]. Donepezil belongs to the important class of acetylcholinesterase 
inhibitors (AChEIs) [24]. The results of the interaction of donepezil with cystatin 
are given below.
5.2 Intrinsic fluorescence studies of cystatin in the presence of donepezil
Cystatin (1 𝜇M) was incubated with various concentrations of donepezil vary-
ing from 2 to 10 𝜇M for 30 min. The fluorescence was recorded in the wavelength 
region of 300–400 nm after exciting the protein solution at 280 nm for total 
protein fluorescence. Donepezil caused unfolding of the cystatin as indicated by 
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enhancement in fluorescence intensity accompanied by the red shift of 40 nm 
as compared to –max of native cystatin (340 nm), while the drug (native) 
shows –max at 370 nm. However at 1.6 𝜇M, when it forms complex with cystatin, 
there was a shift in –max of 10 nm with significant enhancement in fluorescence 
intensity (Figure 4).
Cystatin (1 𝜇M) was incubated with various concentrations of donepezil 
varying from 0.16 to 1.6 𝜇M for 30 min. The fluorescence was taken in the range 
of wavelength 300–400 nm after exciting the protein solution at 280 nm for total 
protein fluorescence. The slits were set at 10 nm for excitation and emission. The 
path length of the sample was 1 cm in the final reaction volume of 1 mL in 0.05 M 
sodium phosphate buffer pH 7.5.
5.3 UV-vis spectra of cystatin in the presence and absence of donepezil
Cystatin concentrations were fixed at 1 𝜇M, while the donepezil concentrations 
varied from 0.16 to 1.6 𝜇M. Absorption spectra of native cystatin and in the pres-
ence and absence of donepezil were recorded in the range of 200–300 nm. The UV 
absorption intensity of cystatin increased with increasing concentration of donepe-
zil concentration; however, the slight decrease in absorption intensity may be due to 
disruption or perturbation of absorbing groups (Figure 5).
5.4 Inhibitory activity of cystatin in the presence of donepezil
A change in the inhibitory activity of cystatin with increasing concentration 
of donepezil is shown in Table 1. The effect of donepezil on cystatin function was 
assessed by monitoring its changes in antiproteolytic activity by caseinolytic assay 
of papain [21]; 1 𝜇M of cystatin was incubated with increasing concentration of 
Figure 4. 
Fluorescence spectra of cystatin in the presence and absence of donepezil. Cystatin (1 μM) was incubated with 
various concentration of Donepezil varying from 0.16 to 1.6 μM for 30 min. The fluorescence was recorded in the 
wavelength region 300–400 nm after exciting the protein solution at 280 nm for total protein fluorescence. The 
slits were set at 10 nm for excitation and emission. The path length of the sample was 1 cm in the final reaction 
volume of 1 ml in 0.05 M sodium phosphate buffer pH 7.5.
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donepezil (0.16–1.6 𝜇M). Exposure of cystatin to increasing concentration of done-
pezil resulted in rapid decline of antiproteolytic activity; 85% decline in the activity 
was seen at 1.6 𝜇M of donepezil with more than half of the inactivation of cystatin 
which was taking place at concentration as low as 0.32 𝜇M.
Table 1 shows changes in the inhibitory activity of brain cystatin after its incuba-
tion for its inhibitory activity with increasing concentrations of donepezil. Cystatin 
(1 𝜇M) was treated with varying concentrations of donepezil (0.16–1.6 𝜇M) for 
30 min in the final reaction volume of 1 mL in 0.05 M sodium phosphate buffer pH 7.5.
5.5 2-D gel electrophoresis
Purity of brain cystatin was confirmed by 2-D gel electrophoresis; purified cys-
tatin was run in one dimension on the isoelectric focusing, and after this, it was run in 
second dimension on 12.5% PAGE. On 2-D gel electrophoresis, BC migrated as a single 
S.no Drug concentration % Remaining inhibitory activity of cystatin
1 Cystatin alone 100
2 Cystatin + 0.16 μM donepezil 57 ± 0.623
3 Cystatin + 0.32 μM donepezil 40 ± 0.938
4 Cystatin + 0.64 μM donepezil 38 ± 0.772
5 Cystatin + 0.96 μM donepezil 24 ± 0.932
6 Cystatin + 1.6 μM donepezil 15 ± 0.680
All data are expressed as mean ± SE for three different sets of experiments; statistical significance was conducted 
employing one-way ANOVA. A probability level of 0.05 was selected showing that results are significant.
The table shows changes in the inhibitory activity of brain cystatin after its incubation for its inhibitory activity 
with increasing concentrations of donepezil. Cystatin (1 μM) is treated with varying concentrations of donepezil 
(0.16–1.6 μM) for 30 min in the final reaction volume of 1 ml in 0.05 M sodium phosphate buffer pH 7.5.
Table 1. 
Inhibitory activity of cystatin in the presence of donepezil.
Figure 5. 
UV-vis spectra of cystatin in the presence and absence of donepezil. Cystatin concentrations were fixed at 1 μM, 
while the donepezil concentration was varied from 0.16 to 1.6 μM. Absorption spectra of native cystatin in the 
presence and absence of donepezil were recorded in the range of 200–300 nm cuvette of 1 cm path length for 
30 min in the final reaction volume of 1 ml in 0.05 M sodium phosphate buffer pH 7.5.
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Figure 6. 
2-D gel electrophoresis of purified BC: after isoelectric focusing, IPG was run horizontally over 12.5% gel 
between the glass slabs. A single dot was obtained toward the negative side of the IPG strip.
dot further supporting the purity nature of BC. The position of the spot was approxi-
mately in the range of 7–8 pH on IPF strip (pH 3–10) suggesting the pl of BC as 7–8.
All data are expressed as mean ± SE for three different sets of experiments; 
statistical significance was conducted employing one-way ANOVA. A probability 
level of 0.05 was selected showing that results are significant (Figure 6).
6. Discussion
The drug inducing changes in protein function leading to adverse side effects is 
the area of continual scientific investigation [25, 26].
Even small structural differences in protein conformation can lead to drastic changes 
in functional parameters [26]. Addition of small molecules such as many drugs, par-
ticularly those with local anesthetics, tranquilizers, and antidepressants, can bind to the 
native state and can alter the delicate balance of various interactions in proteins [27–30].
The adverse drug reactions are triggered due to gathering of drug molecules 
at localized sites in the body causing their elevated concentration [31] and 
ligand-induced protein structure conformational changes [32]. The drugs used as 
medical therapy are unable to act in the specified area because of these intricate 
mechanisms; therefore, all the varied external parameters are taken into account 
which combine the study of the conformational modifications in proteins along 
with drugs resulting complexes causing any side effect which are paramount 
for the study. These studies enable us to understand how ligand affinity can be 
planned and how the protein conformation upon complexation can be managed 
[26] which is decisive in a massive range of imperative biochemical phenomena.
In the present work and structural and functional analyses of cystatin, a protein 
ubiquitously present in mammalian cells and tissues was studied which showed 
a significant increase in fluorescence intensity due to unfolding of cystatin in the 
presence of donepezil (Figure 4). Such kind of changes have also been documented 
earlier, after interaction of ligands (phytohormones, cytokinins, abscisic and gib-
berellic acids) with wheat germ agglutinin resulting in 60% increase in fluorescence 
intensity of native protein [33].
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Donepezil-cystatin complexation showed 40 nm red shift in λmax indicating 
exposure of aromatic residues to the solvent caused by conformational changes in 
the protein [34, 35]. Absorption spectral measurements of cystatin in the presence 
of drug showed a peak noticeable at 275 and 210 nm in spectra obtained at 0.16 𝜇M 
donepezil concentration (Figure 5). Suggesting changes mainly due to tryptophan 
and tyrosine residues [36].
Thus, the results indicate that the UV absorption and fluorescence emission 
changes in donepezil-mediated interaction are due to conformational changes in 
cystatin mainly arising from interaction affecting the chromophoric groups of the 
protein which produce significant effect on the activity of cystatin. The study shows 
that in the presence of donepezil, cystatin gets unfolded which is a side effect of 
donepezil.
There is a gradual decline in the cystatin activity with increasing drug concen-
tration resulting in 62% loss at 0.64 𝜇M donepezil (Table 1). Further magnitude 
of decline was relatively smaller with increasing drug concentration up to 1.6 
𝜇M. Cystatin retained only 15% of its antiproteolytic potential.
The knowledge about the pharmacokinetics and pharmacodynamics of the 
drug-protein interaction continues to expand. The increased information available 
to clinicians might help in optimizing the use of these agents in the management of 
patients with Alzheimer’s disease and other diseases. The clinical utility of measur-
ing these parameters in daily practice awaits further research [37].
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